Artelo Biosciences, Inc. Enters Securities Purchase Agreements and Issues Bridge Notes

Key Highlights from the Report

• Artelo Biosciences, Inc. (Nasdaq: ARTL) has entered into Securities Purchase Agreements with accredited investors, resulting in the issuance of convertible promissory notes (“Bridge Notes”).
• The agreements were formalized on March 12, 2026, with the official report filed on March 18, 2026.
• The Bridge Notes have a combined principal amount of \$350,300, split across two notes: one for \$237,300 and another for \$113,000.
• These notes carry a one-time interest charge of 12%, and are structured for repayment in five monthly installments.
• The notes are convertible into shares of Artelo’s common stock upon an Event of Default, giving holders rights to convert outstanding principal and interest into equity at specified conversion prices.
• Artelo’s common stock is currently listed on the Nasdaq Stock Market LLC under the trading symbol ARTL.
• The proceeds from the sale of notes are earmarked for general working capital purposes.
• The company affirms that all outstanding shares of capital stock are fully paid, non-assessable, and free from liens, claims, and encumbrances.
• All securities issued are unregistered and offered under exemptions provided by Section 4(a)(2) and Rule 506(b) of Regulation D, restricting resale unless registered or qualifying for an exemption.

Details of the Bridge Notes

• Principal Amounts:
  • Bridge Note 1: \$237,300
  • Bridge Note 2: \$113,000
• Interest: 12% one-time charge applied on issuance.
• Repayment: Five monthly payments, totaling \$265,776 for Note 1 and \$126,560 for Note 2.
• Events of Default:
  • Failure to pay principal or interest when due.
  • Failure to issue conversion shares or remove transfer restrictions.
  • Bankruptcy, insolvency, or liquidation proceedings.
  • Delisting from Nasdaq, NYSE, or NYSE American.
  • Failure to comply with SEC reporting requirements.
  • Cessation of operations or admission of inability to pay debts as they come due.
  • Restatement of financial statements affecting rights of noteholders.
  • Replacement of transfer agent without proper notice or process.
• Conversion Rights:
  • Upon default, holders may convert all or part of the outstanding note into fully paid, non-assessable shares of common stock.
  • Conversion price and number of shares are specified by agreement and may be subject to adjustment.
  • Restrictions apply to transfer of shares unless registered or exempt.
  • Company must remove restrictive legends if shares are eligible for sale under an exemption (e.g., Rule 144) or are registered.
• Legal and Compliance:
  • Artelo must maintain corporate existence and comply with SEC reporting as long as any notes are outstanding.
  • Failure to comply with covenants or representations constitutes an Event of Default, giving holders potential remedies including acceleration or conversion.
  • The company is not considered an investment company under the Investment Company Act of 1940.

Potentially Price-Sensitive Items for Shareholders

• Convertible Debt Issuance: The issuance of convertible notes may potentially dilute existing shareholders if conversion occurs, especially in the event of default.
• Events of Default Risk: Multiple triggers could allow investors to convert debt to equity, potentially increasing share supply and affecting share price.
• SEC Compliance: Failure to maintain SEC reporting or listing on Nasdaq is an Event of Default, which could have significant negative implications for share value.
• Financial Statement Restatement: Any material adverse effect related to restatement of financials may trigger default and conversion, possibly impacting investor confidence and share price.
• Sale and Transfer Restrictions: Shares issued upon conversion may be subject to restrictive legends, limiting liquidity unless registered or exempt.
• Use of Proceeds: Funds raised are for working capital, indicating the company may be addressing liquidity needs. Investors should monitor for further fundraising or operating developments.

Investor Considerations

• Artelo’s agreements reflect a need for working capital and reliance on convertible debt, which may signal liquidity concerns.
• Convertible notes carry risk of dilution and may pressure share price if converted, particularly if triggered by adverse events.
• The company’s continued compliance with SEC reporting and Nasdaq listing is crucial; any lapses may result in default and conversion, potentially affecting share value.
• Shareholders should monitor for developments in financial reporting, operational performance, and compliance with covenants under the agreements.

Conclusion

The announcement of the Securities Purchase Agreements and Bridge Notes by Artelo Biosciences, Inc. constitutes a potentially price-sensitive event. The issuance of convertible debt, the outlined Events of Default, and the possibility of share dilution are material factors that could impact the company’s share price and investor sentiment. Shareholders are advised to closely monitor Artelo’s compliance with financial and operational covenants, SEC reporting, and Nasdaq listing requirements.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. The information presented is based on company filings and may be subject to change.

View ARTELO BIOSCIENCES, INC. Historical chart here